3rd Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Period 3rd Quarter 2013 Filed Oct 24, 2013 Signed by Francesca Fierro O'Reilly, Vice President, Government Relations

Official filing
Firm
AMERICAN CLINICAL LABORATORY ASSN
Client
AMERICAN CLINICAL LABORATORY ASSN
Income
—
Expenses
$265,098
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI New —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Congressional Budget Office (CBO); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office

Medicare/Medicaid MMM

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI New —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Government Accountability Office (GAO); SENATE; White House Office; Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Management & Budget (OMB)

Budget/Appropriations BUD

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI New —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: SENATE; Government Accountability Office (GAO); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI New —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Medicare Payment Advisory Commission (MedPAC); White House Office; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.